MANEVeradermics Incorporated Common Stock
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting a…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Veradermics (MANE) Positioned to Disrupt Hair Loss Market Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […] | IInsider Monkey | |
 Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months Veradermics Incorporated on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. The company said the treatment produced consistent hair growth, demonstrated an early onset of activity, and... | ||
Sector Update: Healthcare Stocks Advance Late Afternoon Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the | MMT Newswires | |
 Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women Veradermics (NYSE:MANE) said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment. Chief Executive Officer Dr. Reid Waldman said t | ||
IInsider Monkey | ||